Skip to content
azilsartan

Structure via PubChem · Public domain (PubChem)

EntityQ27074832· pop 21· linked from 87 articles

azilsartan

Sign in to save

Also known as TAK 536, TAK-536, TAK536

Azilsartan, sold under the brand name Edarbi among others, is used for the treatment of hypertension. It is used as the prodrug azilsartan medoxomil, is an angiotensin II receptor antagonist, and was developed by Takeda.

Key facts

Drug.legal_status
Rx-only
Drug.bioavailability
60%
Drug.Verifiedfields
changed
Drug.Watchedfields
changed
Drug.verifiedrevid
456077928
Drug.image
Azilsartan.svg
Drug.image_class
skin-invert-image
Drug.tradename
Edarbi, Azilva
Drug.MedlinePlus
a611028
Drug.DailyMedID
Azilsartan
Drug.routes_of_administration
By mouth
Drug.ATC_prefix
C09
Drug.ATC_suffix
CA09
Drug.legal_CA
Rx-only
Drug.legal_UK
POM
Drug.legal_US
Rx-only
Drug.legal_EU
Rx-only
Drug.metabolism
CYP2C9

via Wikipedia infobox

Chemical data

Formula
C25H20N4O5
Molecular weight
456.4 g/mol
IUPAC name
2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
SMILES
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
InChIKey
KGSXMPPBFPAXLY-UHFFFAOYSA-N
XLogP
4.4
Polar surface area
115 Ų
H-bond donors
2
H-bond acceptors
7
Formal charge
0

via PubChem

~6 min read

Encyclopedic overview

9 sections
Contents
  • Medical uses
  • Contraindications
  • Interactions
  • Pharmacology
  • Mechanism of action
  • Pharmacokinetics
  • Chemistry
  • History
  • References

{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 456077928 | image = Azilsartan.svg | image_class = skin-invert-image | width = | alt = | caption = | USAN =

| pronounce = | tradename = Edarbi, Azilva | Drugs.com = | MedlinePlus = a611028 | DailyMedID = Azilsartan | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = C09 | ATC_suffix = CA09 | ATC_supplemental =

Excerpted from Wikipedia’s “azilsartan” article, available under the CC BY-SA 4.0 licence.

Gallery (2)